Phase I trial of erlotinib with radiation therapy in patients with glioblastoma multiforme: Results of North Central Cancer Treatment Group protocol N0177 Academic Article uri icon

Overview

MeSH Major

  • Brain Neoplasms
  • Glioblastoma
  • Quinazolines
  • Receptor, Epidermal Growth Factor

abstract

  • Toxicity is acceptable at the current doses of erlotinib plus RT. The study was modified to include concurrent and adjuvant temozolomide, and accrual is in progress.

publication date

  • July 15, 2006

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1016/j.ijrobp.2006.01.018

PubMed ID

  • 16626884

Additional Document Info

start page

  • 1192

end page

  • 9

volume

  • 65

number

  • 4